Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;16(10):e009905.
doi: 10.1161/CIRCOUTCOMES.123.009905. Epub 2023 Sep 13.

Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative

Arco J Teske  1 , Rohit Moudgil  2 , Teresa López-Fernández  3 , Ana Barac  4 , Sherry Ann Brown  5 , Anita Deswal  6 , Tomas G Neilan  7 , Sarju Ganatra  8 , Husam Abdel Qadir  9 , Venu Menon  2 , Aaron L Sverdlov  10 , Richard K Cheng  11 , Silvia Makhoul  12 , Arjun K Ghosh  13   14   15 , Sebastian Szmit  16 , Vlad Zaha  17 , Daniel Addison  18 , Lili Zhang  19 , Joerg Herrmann  20 , Jun H Chong  21 , Vivek Agarwala  22 , Zaza Iakobishvili  23 , Patricia Guerrero  24 , Eric H Yang  25 , Monika Leja  26 , Nausheen Akhter  27 , Avirup Guha  28 , Tochukwu M Okwuosa  29 , Carolina Carvalho Silva  30 , Patrick Collier  2 , Jeanne DeCara  31 , Brenton Bauer  32 , Carrie E Lenneman  33 , Diego Sadler  34
Affiliations
Review

Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative

Arco J Teske et al. Circ Cardiovasc Qual Outcomes. 2023 Oct.

Abstract

Background: Global collaboration in cardio-oncology is needed to understand the prevalence of cancer therapy-related cardiovascular toxicity in different risk groups, practice settings, and geographic locations. There are limited data on the socioeconomic and racial/ethnic disparities that may impact access to care and outcomes. To address these gaps, we established the Global Cardio-Oncology Registry, a multinational, multicenter prospective registry.

Methods: We assembled cardiologists and oncologists from academic and community settings to collaborate in the first Global Cardio-Oncology Registry. Subsequently, a survey for site resources, demographics, and intention to participate was conducted. We designed an online data platform to facilitate this global initiative.

Results: A total of 119 sites responded to an online questionnaire on their practices and main goals of the registry: 49 US sites from 23 states and 70 international sites from 5 continents indicated a willingness to participate in the Global Cardio-Oncology Registry. Sites were more commonly led by cardiologists (85/119; 72%) and were more often university/teaching (81/119; 68%) than community based (38/119; 32%). The average number of cardio-oncology patients treated per month was 80 per site. The top 3 Global Cardio-Oncology Registry priorities in cardio-oncology care were breast cancer, hematologic malignancies, and patients treated with immune checkpoint inhibitors. Executive and scientific committees and specific committees were established. A pilot phase for breast cancer using Research Electronic Data Capture Cloud platform recently started patient enrollment.

Conclusions: We present the structure for a global collaboration. Information derived from the Global Cardio-Oncology Registry will help understand the risk factors impacting cancer therapy-related cardiovascular toxicity in different geographic locations and therefore contribute to reduce access gaps in cardio-oncology care. Risk calculators will be prospectively derived and validated.

Keywords: cardiology; cardiotoxicity; cardiovascular disease; hematology; myocarditis.

PubMed Disclaimer

Conflict of interest statement

Disclosures Dr Teske has received speaker fees from Philips and Abbott; consulting from Nordic Pharma. Dr Neilan reports consulting from BMS, Abbvie, Sanofi, Genentech, Roche, and C4-Therapeutics; grant funding from BMS and AZ. Dr López-Fernández has received speaker fees from Philips, Janssen, and Incyte. Dr Szmit has received speaker fees from Amgen, Angelini, Astra Zeneca, Bayer, Bristol-Myers Squibb, Gilead, and Pfizer. Dr Guha is supported by American Heart Association-Strategically Focused Research Network Grant in Disparities in Cardio-Oncology (847740 and 863620). Dr Iakobishvili has received speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Novo-Nordisk, and Bayer. Dr Sverdlov is supported by the National Heart Foundation of Australia Future Leader Fellowship (Award ID 106025) and reports research grants from the Medical Research Future Fund (Australia), NSW Health (Australia), Cancer Institute NSW (Australia), Hunter Medical Research Institute (Australia), Biotronik, RACE Oncology, Bristol Myer Squibb, Roche Diagnostics, and Vifor; and personal speaker fees from Novartis, Bayer, Bristol Myer Squibb, AstraZeneca, and Boehringer Ingelheim. The other authors report no conflicts.

Figures

Figure 1.
Figure 1.. Data collection design for pillar I: breast cancer.
Data collection and entry of baseline and follow-up variables are shown. Specific data collection is modeled to each pillar to ensure both complete and relevant data collection. CAD indicates coronary artery disease; CV, cardiovascular; GLS, global longitudinal strain; LV, left ventricle; and LVEF, left ventricular ejection fraction.
Figure 2.
Figure 2.. Global Cardio-Oncology Registry (G-COR) committees.
See Appendix A for detailed information on committee members. AI indicates artificial intelligence; CO, cardio-oncology; and ICI, immune check point inhibitors.
Figure 3.
Figure 3.. World map of participating centers.
Information and geographic distribution of the Global Cardio-Oncology Registry (G-COR) across the 5 continents is shown. N indicates the number of participating centers in each continent. The pie charts show the details of the size of the participating centers. Color-legend is depicted on the top right. CO indicates cardio oncology.
Figure 4.
Figure 4.. Survey results.
This shows feedback on the main areas of research interest (sites could prioritize the different research topics). Most centers indicated BC as the primary topic of research, HM was most often mentioned as the second topic, and followed by ICI. The absolute number of responses is indicated on the vertical axis. BC indicates breast cancer; G-COR, Global Cardio-Oncology Registry; HM, hematologic malignancies; and ICI, immune checkpoint inhibitors.
Figure 5.
Figure 5.. Description of Global Cardio-Oncology Registry (G-COR) future goals and landmarks.
See this image and copyright information in PMC

Comment in

References

    1. Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem J, Barlesi F, Farnault L, Charbonnier A, Mirabel M, Champiat S, et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc. 2020;9:e018403. doi: 10.1161/JAHA.120.018403 - DOI - PMC - PubMed
    1. Herrmann J, López-Fernández T, Lyon AR. The year in cardiovascular medicine 2021: cardio-oncology. Eur Heart J. 2022;43:857–862. doi: 10.193/eurheartj/ehab891 - DOI - PubMed
    1. Ky B. JACC: CardioOncology: poised to serve a maturing, collaborative field. JACC CardioOncol. 2019;1:131–132. doi: 10.1016/j.jaccao.2019.06.001 - DOI - PMC - PubMed
    1. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, van der Meer P, Cohen Solal A, Zamorano J-L, Jerusalem G, Moonen M, et al. Cardio-Oncology Services: rationale, organization, and implementation: a report from the ESC Cardio-Oncology council. Eur Heart J. 2019;40:1756–1763. doi: 10.1093/eurheartj/ehy453 - DOI - PubMed
    1. Teske AJ, Linschoten M, Kamphuis JAM, Naaktgeboren WR, Leiner T, van der Wall E, Kuball J, van Rhenen A, Doevendans PA, Cramer MJ, et al. Cardio-oncology: an overview on outpatient management and future developments. Netherlands Heart Journal. 2018;26:521–532. doi: 10.1007/s12471-018-1148-7 - DOI - PMC - PubMed